Novartis Says FDA Approves Menveo in Kids, Not Infants
This article is for subscribers only.
U.S. regulators approved Novartis AG’s Menveo meningococcal vaccine for use in children from 2 years of age, though they requested more information on use of the shot in infants.
The company will resubmit the application to the Food and Drug Administration in the coming months for use of the vaccine in babies aged 2 months to 12 months, Basel, Switzerland-based Novartis said today in a statement.